CO2023010002A2 - Fracciones que prolongan la semivida y métodos de uso de estas - Google Patents
Fracciones que prolongan la semivida y métodos de uso de estasInfo
- Publication number
- CO2023010002A2 CO2023010002A2 CONC2023/0010002A CO2023010002A CO2023010002A2 CO 2023010002 A2 CO2023010002 A2 CO 2023010002A2 CO 2023010002 A CO2023010002 A CO 2023010002A CO 2023010002 A2 CO2023010002 A2 CO 2023010002A2
- Authority
- CO
- Colombia
- Prior art keywords
- life
- prolong
- fractions
- methods
- prolonging
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 229960000074 biopharmaceutical Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La descripción se relaciona generalmente con la biología y la medicina, y más particularmente se relaciona con compuestos que actúan como fracciones que prolongan la semivida (t½) para usar con productos terapéuticos, especialmente para mejorar la t½ de productos terapéuticos de base biológica (es decir, biofármacos o productos biológicos). La descripción se refiere además a fusiones y conjugados que incluyen uno o más de los compuestos que actúan como fracciones que prolongan la t½, así como composiciones farmacéuticas que incluyen los mismos y su uso en el tratamiento de diversas afecciones, enfermedades o trastornos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163144696P | 2021-02-02 | 2021-02-02 | |
PCT/US2022/014728 WO2022169757A1 (en) | 2021-02-02 | 2022-02-01 | Half-life extending moieties and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023010002A2 true CO2023010002A2 (es) | 2023-09-08 |
Family
ID=80735776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0010002A CO2023010002A2 (es) | 2021-02-02 | 2023-07-27 | Fracciones que prolongan la semivida y métodos de uso de estas |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP4288452A1 (es) |
JP (1) | JP2024506145A (es) |
KR (1) | KR20230137342A (es) |
CN (1) | CN116802209A (es) |
AU (1) | AU2022217754A1 (es) |
CA (1) | CA3204225A1 (es) |
CL (1) | CL2023002285A1 (es) |
CO (1) | CO2023010002A2 (es) |
CR (1) | CR20230366A (es) |
DO (1) | DOP2023000149A (es) |
EC (1) | ECSP23058246A (es) |
IL (1) | IL304219A (es) |
MX (1) | MX2023009006A (es) |
PE (1) | PE20240233A1 (es) |
WO (1) | WO2022169757A1 (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110049997B (zh) * | 2016-12-07 | 2023-09-22 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白单可变结构域 |
US11384141B2 (en) * | 2018-04-24 | 2022-07-12 | National Research Council Of Canada | Serum albumin binding antibodies for tuneable half-life extension of biologics |
TW202120536A (zh) * | 2019-07-31 | 2021-06-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
-
2022
- 2022-02-01 EP EP22709849.8A patent/EP4288452A1/en active Pending
- 2022-02-01 JP JP2023546450A patent/JP2024506145A/ja active Pending
- 2022-02-01 CA CA3204225A patent/CA3204225A1/en active Pending
- 2022-02-01 MX MX2023009006A patent/MX2023009006A/es unknown
- 2022-02-01 CR CR20230366A patent/CR20230366A/es unknown
- 2022-02-01 CN CN202280012629.0A patent/CN116802209A/zh active Pending
- 2022-02-01 KR KR1020237025927A patent/KR20230137342A/ko unknown
- 2022-02-01 AU AU2022217754A patent/AU2022217754A1/en active Pending
- 2022-02-01 PE PE2023002220A patent/PE20240233A1/es unknown
- 2022-02-01 WO PCT/US2022/014728 patent/WO2022169757A1/en active Application Filing
-
2023
- 2023-07-03 IL IL304219A patent/IL304219A/en unknown
- 2023-07-27 CO CONC2023/0010002A patent/CO2023010002A2/es unknown
- 2023-07-27 DO DO2023000149A patent/DOP2023000149A/es unknown
- 2023-08-01 EC ECSENADI202358246A patent/ECSP23058246A/es unknown
- 2023-08-02 CL CL2023002285A patent/CL2023002285A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3204225A1 (en) | 2022-08-11 |
PE20240233A1 (es) | 2024-02-16 |
DOP2023000149A (es) | 2023-09-15 |
CL2023002285A1 (es) | 2024-02-23 |
CR20230366A (es) | 2023-10-03 |
IL304219A (en) | 2023-09-01 |
ECSP23058246A (es) | 2023-09-29 |
KR20230137342A (ko) | 2023-10-04 |
MX2023009006A (es) | 2023-08-08 |
AU2022217754A1 (en) | 2023-07-27 |
EP4288452A1 (en) | 2023-12-13 |
WO2022169757A1 (en) | 2022-08-11 |
JP2024506145A (ja) | 2024-02-09 |
CN116802209A (zh) | 2023-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
CR11200A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k | |
ECSP109934A (es) | Compuesto - 946 | |
ECSP055613A (es) | Derivados de pirimidina y su uso como moduladores cb2 | |
UY27943A1 (es) | Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos | |
CL2019002671A1 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1. | |
CL2008003873A1 (es) | Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer | |
ECSP077235A (es) | Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa | |
ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
CR9667A (es) | Derivados de benzamida y usos relacionados con los mismos | |
UY30267A1 (es) | Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones | |
UY30229A1 (es) | Tetrahidro-pirimidoazepinas como moduladores de trpv1 | |
CO2022001210A2 (es) | Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes | |
CL2007001748A1 (es) | Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras. | |
CL2008002356A1 (es) | Sulfoxidos de piperazina-amida; sus procesos de preparacion; las composiciones farmaceuticas que los contienen; y su uso en el tratamiento de enfermedades que se modulan con agonistas lxr alfa y/o beta. | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
HN2003000162A (es) | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen. | |
CO2022000749A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
BR112022008497A2 (pt) | Derivados terapêuticos da interleucina-22 | |
BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
SV2011003839A (es) | Agentes antifungicos | |
ECSP23058246A (es) | Fracciones que prolongan la semivida y métodos de uso de estas | |
CL2007002019A1 (es) | Compuestos derivados de sulfoximinas sustituidas, inhibidores de receptores tie2; metodos de preparacion;compuesto intermediario;composicion farmaceutica que comprende a uno de los compuestos;y uso del compuesto en la preparacion de medicamentros para el tratamiento tumores y/o metastasis. | |
BR112019008516A2 (pt) | derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo |